

## Agenda of financial events 2014

PRINCETON, N.J. and PARIS – January 6, 2014 - <u>STENTYS</u> (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing<sup>®</sup> stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2014.

Event	Date *
Q4 Full Year Sales 2013	Thursday, January 23, 2014
Full-Year Results 2013	Thursday, March 13, 2014
Q1 Sales 2014	Thursday, April 24, 2014
Q2 Sales 2014	Thursday, July 24, 2014
Half-Year Results 2014	Thursday, August 28, 2014
Q3 Sales 2014	Thursday, October 23, 2014
	Financial year ended 31 December

Financial year ended 31 December

\* Subject to modification. Press releases are distributed after the financial markets closure.

## About STENTYS:

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing<sup>®</sup> Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. *More information is available at www.stentys.com.* 

## Contacts

## **STENTYS**

Stanislas Piot CFO Tel.: +33 (0)1 44 53 99 42 <u>stan.p@stentys.com</u>

STENTYS is listed on Compartment C of the NYSE Euronext Paris ISIN: FR0010949404 – Ticker: STNT

Europe: NewCap. Investor Relations & Financial Communications Dusan Oresansky / Pierre LaurentTel.: +33 (0)1 44 71 94 93 stentys@newcap.fr

US: MacDougall Biomedical Communications Kari Watson, Tel.: +1 781 235 3060 Christine Labaree, Tel.: +1 650 339 7533 stentys@macbiocom.com

